Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Clinical trial NCT06704269 · RECRUITING
Trial details
- NCT number
- NCT06704269
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-22
- Primary completion
- 2029-10-26
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.